International Study Supports Conventional WISDOM About Hormone Therapy

A new report supplies more evidence that HT may increase cardiovascular risk in older women.

Investigators for the Women’s International Study of long Duration Oestrogen after Menopause (WISDOM) have now reported results. Participants were postmenopausal women (median age, 62.8 years) from general practices in the U.K., Australia, and New Zealand. The study goal was to assess the long-term risks and benefits of combined hormone therapy (HT, estrogen plus progestogen) versus placebo, and of estrogen-only therapy versus combined HT. Primary outcomes of interest were major cardiovascular disease, osteoporotic fractures, and breast cancer. Although the study design called for 10 years of treatment, WISDOM was closed after a median follow-up time of just under 1 year, after the termination of the Women’s Health Initiative (WHI) study in…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

International Study Supports Conventional WISDOM About Hormone Therapy

Topics

Reviewing Author